Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | TERT | O14746 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7813040 | 0.98 | SMN1; SMN2 (0.60) | SMN1; SMN2TERTRAB9ALMNANPC1 | |
| SCHEMBL6361850 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2TERTRAB9ALMNANPC1 | |
| SCHEMBL16972520 | 0.86 | SMN1; SMN2 (0.87) | SMN1; SMN2TERTRAB9ALMNANPC1 | |
| SCHEMBL5875816 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2TERTRAB9ALMNANPC1 | |
| SCHEMBL6446624 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2TERTRAB9ALMNANPC1 | |
| SCHEMBL8055642 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2TERTRAB9ALMNANPC1 | |
| SCHEMBL6717347 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2TERTKDM4EMAPK8DAPK3 | |
| SCHEMBL8184759 | 0.82 | RAB9A (0.48) | SMN1; SMN2TERTRAB9ALMNANPC1 | |
| SCHEMBL891 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2TERTRAB9ALMNANPC1 | |
| SCHEMBL13742735 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2TERTMAPK8DAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081847-A | Method for synthesizing 5-substituted pyrazolo [4,3-d ] pyrimidine-7 (6H) -ketone derivative by photocatalysis | 淮阴工学院 | 2025-06-03 | — | — | CN | claimed |
| CN-118878542-A | Haomaxidenafil derivative and synthesis method and application thereof | 西安市食品药品检验所 | 2024-11-01 | — | — | CN | claimed |
| CN-115785101-B | Phenylpiperazine structure-containing nafil compound and preparation method thereof | 西安市食品药品检验所 | 2023-10-13 | — | — | CN | claimed |
| CN-115785101-A | Phenylpiperazine structure-containing nafil compound and preparation method thereof | 西安市食品药品检验所 | 2023-03-14 | — | — | CN | claimed |
| EP-3099689-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2022-01-26 | — | — | EP | claimed |
| CN-113372350-A | Deuterated sildenafil as well as preparation method and application thereof | 深圳鼎邦生物科技有限公司 | 2021-09-10 | — | — | CN | claimed |
| CN-111005033-B | Electro-reduction preparation method of sildenafil intermediate | 浙江大学 | 2020-10-16 | — | — | CN | claimed |
| CN-111005033-A | Electro-reduction preparation method of sildenafil intermediate | 浙江大学 | 2020-04-14 | — | — | CN | claimed |
| CN-108822111-A | A kind of 5-（2- ethoxyl phenenyl）The preparation method of -1- methyl -3- propyl -1H- pyrazolo [4,3-d] pyrimidin-7-ones | 温州医科大学 | 2018-11-16 | — | — | CN | claimed |
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-10 | — | — | US | claimed |
| WO-2015114647-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-08-06 | — | — | WO | claimed |
| CN-104211705-A | Preparation method of sildenafil | HEFEI KEDA BIOLOG TECHNOLOGY CO LTD | 2014-12-17 | — | — | CN | claimed |
| CN-103755709-A | Microwave-assisted preparation method of sildenafil derivatives | UNIV GUANGDONG PHARM | 2014-04-30 | — | — | CN | claimed |
| CN-103613597-A | Preparation process of sildenafil citrate | ANHUI YOUCARE KAIYUE PHARMACEUTICAL CO LTD | 2014-03-05 | — | — | CN | claimed |
| CN-103044331-A | Novel method for preparing Sildenafil intermediate 4-amino-1-methyl-3-n-propyl-pyrazole-5-formamide | CHANGZHOU YABANG PHARMACEUTICAL INST CO LTD | 2013-04-17 | — | — | CN | claimed |
| CN-103044330-A | New green synthesis process of sildenafil intermediate compound 4-amino-1-methyl-3-n-propyl pyrazole-5-formamide | CHANGZHOU YABANG PHARMACEUTICAL INST CO LTD | 2013-04-17 | — | — | CN | claimed |
| US-6960661-B2 | [7-(3-chloro-4-methoxybenzlamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid, synthesis thereof and intermediates used therein | MERCK PATENT GMBH (DE) | 2005-11-01 | — | — | US | claimed |
| US-20040053945-A1 | Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative | MERCK PATENT GMBH (DE) | 2004-03-18 | — | — | US | claimed |
| EP-1358189-A1 | PROCESS FOR THE PREPARATION OF A PYRAZOLO 4,3-D]PYRIMIDINE DERIVATIVE | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | claimed |
| WO-2002059126-A1 | PROCESS FOR THE PREPARATION OF A PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVE | MERCK PATENT GMBH (DE) | 2002-08-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | SMN1; SMN2 1902/4885TERT 4032/4885RAB9A 1632/4885 |
| US-20040053945-A1 | Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative | HPD, DDC, KMO | SMN1; SMN2 3289/4885TERT 2859/4885RAB9A 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.